

### **[Brief CV]**

Dr. Miyamoto is Professor of Pediatrics, the Jack Cooper Millisor Chair of Pediatric Heart Disease, the Director of the Cardiomyopathy Program, and a transplant cardiologist at Children's Hospital Colorado and the University of Colorado Denver. Her clinical expertise includes the care of infants and children suffering from various forms of cardiomyopathy and complex congenital heart disease as well as the care of children who have had a heart transplant. Dr. Miyamoto's research interests include studies of molecular adaptation of the failing pediatric heart, identification of novel therapeutic targets, animal model development and biomarker assessment and development. In addition, she performs clinical trials research related to pediatric heart failure and heart transplantation.

Dr. Miyamoto has published over 80 peer-reviewed publications: <https://www.ncbi.nlm.nih.gov/myncbi/shelley.miyamoto.1/bibliography/public/>. Her research lab has been continuously funded by the NIH since 2009 with current grants focusing on the myocardial effects of phosphodiesterase-5 inhibitors in single ventricle congenital heart disease, the study of circulating microRNAs as biomarkers in pediatric dilated cardiomyopathy and as a marker of rejection and coronary artery vasculopathy in pediatric transplant recipients, and she is the director of the angiography core laboratory for the U.S. Department of Defense clinical trial investigating everolimus vs mycophenolate mofetil in pediatric transplant recipients.